Literature DB >> 9974468

Perspectives of commissioners and cancer specialists in prioritising new cancer drugs: impact of the evidence threshold.

R Foy1, J So, E Rous, J H Scarffe.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 9974468      PMCID： PMC1114914          DOI： 10.1136/bmj.318.7181.456

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  12 in total

1.  Cancer treatments rationed by authority.

Authors:  M Halle
Journal:  BMJ       Date:  1996-09-28

2.  Fludarabine in chronic leukaemia.

Authors:  A B Astrow
Journal:  Lancet       Date:  1996-05-25       Impact factor: 79.321

3.  More money is needed to care for patients with cancer.

Authors:  R C Leonard; I E Smith; R E Coleman; J S Malpas; M Nicolson; J Cassidy; A Jones; M B McIllmurray; N S Stuart; P J Woll; J M Whitehouse
Journal:  BMJ       Date:  1997-09-27

4.  Research and development programme begins to bite. Interview by Hilary Bower.

Authors:  J Swales
Journal:  BMJ       Date:  1997-02-15

5.  A purchaser perspective of managing new drugs: interferon beta as a case study.

Authors:  T Walley; S Barton
Journal:  BMJ       Date:  1995-09-23

6.  Gemcitabine: clinical and economic impact in inoperable non-small cell lung cancer.

Authors:  P Koch; N Johnson; J van Schaik; S Andersen; J Blatter; N Bosanquet; K Copley-Merriman; P Drings
Journal:  Anticancer Drugs       Date:  1995-12       Impact factor: 2.248

7.  Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens.

Authors:  P Ross; J Heron; D Cunningham
Journal:  Eur J Cancer       Date:  1996       Impact factor: 9.162

8.  A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.

Authors:  W Jonat; A Howell; C Blomqvist; W Eiermann; G Winblad; C Tyrrell; L Mauriac; H Roche; S Lundgren; R Hellmund; M Azab
Journal:  Eur J Cancer       Date:  1996-03       Impact factor: 9.162

9.  Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients.

Authors:  W Mills; R Chopra; D C Linch; A H Goldstone
Journal:  Br J Haematol       Date:  1994-04       Impact factor: 6.998

10.  Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.

Authors:  W P McGuire; W J Hoskins; M F Brady; P R Kucera; E E Partridge; K Y Look; D L Clarke-Pearson; M Davidson
Journal:  N Engl J Med       Date:  1996-01-04       Impact factor: 91.245
View more
  15 in total

1.  Lack of funding will inhibit evidence based commissioning of cancer treatments.

Authors:  J So; J H Scarffe; E Rous; R Foy
Journal:  BMJ       Date:  2000-01-01

2.  Priority setting for new technologies in medicine: qualitative case study.

Authors:  P A Singer; D K Martin; M Giacomini; L Purdy
Journal:  BMJ       Date:  2000-11-25

Review 3.  A strategy to improve priority setting in health care institutions.

Authors:  Doug Martin; Peter Singer
Journal:  Health Care Anal       Date:  2003-03

Review 4.  Eliciting reasons: empirical methods in priority setting.

Authors:  Andreas Hasman
Journal:  Health Care Anal       Date:  2003-03

Review 5.  Evidence based medicine guidelines: a solution to rationing or politics disguised as science?

Authors:  S I Saarni; H A Gylling
Journal:  J Med Ethics       Date:  2004-04       Impact factor: 2.903

6.  Alignment of practice guidelines with targeted-therapy drug funding policies in Ontario.

Authors:  R Ramjeesingh; R M Meyer; M Brouwers; B E Chen; C M Booth
Journal:  Curr Oncol       Date:  2013-02       Impact factor: 3.677

7.  Provincial elections and timing of cancer drug funding.

Authors:  A Srikanthan; S S Gill; K K W Chan
Journal:  Curr Oncol       Date:  2016-06-09       Impact factor: 3.677

Review 8.  Stated and Revealed Preferences for Funding New High-Cost Cancer Drugs: A Critical Review of the Evidence from Patients, the Public and Payers.

Authors:  Tatjana E MacLeod; Anthony H Harris; Ajay Mahal
Journal:  Patient       Date:  2016-06       Impact factor: 3.883

9.  6-STEPPPs: A Modular Tool to Facilitate Clinician Participation in Fair Decisions for Funding New Cancer Drugs.

Authors:  George P Browman; Braden Manns; Neil Hagen; Carole R Chambers; Anita Simon; Shane Sinclair
Journal:  J Oncol Pract       Date:  2008-01       Impact factor: 3.840

10.  The timing of drug funding announcements relative to elections: a case study involving dementia medications.

Authors:  Sudeep S Gill; Neeraj Gupta; Chaim M Bell; Paula A Rochon; Peter C Austin; Andreas Laupacis
Journal:  PLoS One       Date:  2013-02-27       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.